Drugs - Immunology Flashcards Preview

USMLE > Drugs - Immunology > Flashcards

Flashcards in Drugs - Immunology Deck (29):
1

cyclosporine

MOA: immunosuppressant; calcineurin inhibitor that prevents IL-2 transcription and T cell activation

Use: used to prevent transplant rejection and to treat rheumatoid arthritis

Adverse effects: causes nephrotoxicity, neurotoxicity, HTN

2

tacrolimus

MOA: immunosuppressant; calcineurin inhibitor; blocks T cell activation by preventing IL-2 transcription

Use: used to prevent transplant rejection

Adverse effects: nephrotoxic and neurotoxic, increases risk of diabetes

3

siroliumus

MOA: immunosuppressant; mTOR inhibitor; blocks T and B cell differentiation by preventing response to IL-2

Use: used in kidney transplant to prevent rejection because not nephrotoxic

Adverse effects: anemia, thrombocytopenia, leukopenia

4

daclizumab and basiliximab

MOA: immunosuppressants; monoclonals against IL-2

Use: kidney transplant rejection prevention

Adverse effects: edema, HTN, tremor

5

azathioprine

MOA: immunosuppressant; inhibits lymphocyte proliferation by blocking nucleotide synthesis

Use: prevent transplant rejection; rheumatoid arthritis, Crohn disease, glomerulonephritis

Adverse effects: leukopenia, anemia, thrombocytopenia; toxicity is increased by allopurinol

6

glucocorticoids

MOA: inhibit NF-kappaB; suppresses B and T cell function by decreasing cytokine transcription

Use: prevent transplant rejection; autoimmune disorders; inflammation

Adverse effects: hyperglycemia; osteoporosis; central obesity; muscle breakdown; psychosis; acne; hypertension; cataracts; avascular necrosis, iatrogenic Cushing's syndrome

7

Aldesleukin

MOA: recombinant IL-2

Use: renal cell carcinoma, metastatic melanoma

8

Epoetin alfa

MOA: recombinant EPO

Use: anemia, especially in setting of renal failure

9

Filgrastim

MOA: G-CSF

Use: recovery of bone marrow

10

Sargramostim

MOA: GM-CSF

Use: recovery of bone marrow

11

IFN-alpha

MOA: recombinant cytokine

Use: chronic hepatits B and C, Kaposi sarcoma, malignant melanoma

12

IFN-beta

MOA: recombinant cytokine; reduces inflammation by stimulating suppressor T cells and thus decreasing cytokines

Use: multiple sclerosis

13

IFN-gamma

MOA: recombinant cytokine

Use: chronic granulomatous disease

14

romipostim and eltrombopag

MOA: recombinant cytokines

Use: thrombocytopenia

15

oprelvekin

MOA: recombinant IL-11

Use: thrombocytopenia

16

alemtuzumab

MOA: targets CD52

Use: CLL

17

bevacizumab

MOA: targets VEGF

Use: colorectal cancer, renal cell carcinoma

18

cetuximab

MOA: targets EGFR

Use: stage IV colorectal cancer, head and neck cancer

19

rituximab

MOA: targets CD20

Use: B cell non-hodgkin lymphoma, CLL, rheumatoid arthritis, ITP

20

trastuzumab

MOA: targets HER2/neu

Use: breast cancer

21

Adalimumab and infliximab

MOA: targets soluble TNF-alpha

Use: IBD, rheumatoid arthritis, ankylosing spondylitis, psoriasis

22

Eculizumab

MOA: targets complement protein C5

Use: paroxysmal nocturnal hemoglobinuria

23

Natalizumab

MOA: targets alpha4-integrin which is involved in WBC adhesion

Use: MS, Crohn disease

Adverse effects: risk of PML in patients with the JC virus

24

Abciximab

MOA: targets platelet glycoproteins IIb/IIIa

Use: antiplatelet agent use to prevent ischemic complications in patients undergoing percutaneous coronary intervention

25

Denosumab

MOA: targets RANKL, inhibiting osteoclast maturation

Use: osteoporosis

26

Digoxin immune Fab

MOA: targets digoxin

Use: antidote for digoxin toxicity

27

Omalizumab

MOA: targets IgE and prevents it from binding to Fc

Use: allergic asthma

28

Palivizumab

MOA: targets RSV F protein

Use: RSV prophylaxis for high risk infants

29

Ranibizumab and bevacizumab

MOA: target VEGF

Use: neovascular age-related macular degeneration